Categories
Change Password!
Reset Password!
Omeprazole effectively controls acid peptic disease symptoms across multiple gastrointestinal manifestations in patients with type 2 diabetes mellitus.
Omeprazole therapy produced remarkable improvements in multiple acid peptic disease (APD) symptoms, with complete resolution of flatulence and loss of appetite in Indian patients with type 2 diabetes mellitus (T2DM), according to findings from the PRIDE-1 real-world study.
APD is a frequent gastrointestinal complication in individuals with T2DM, often contributing to poor quality of life and increased healthcare burden. Although proton pump inhibitors (PPIs) are commonly prescribed for symptom control, evidence from routine clinical practice in diabetic populations has been limited. To address this gap, investigators conducted the multicenter PRIDE-1 retrospective study to evaluate the effectiveness and safety of omeprazole using electronic medical records from Indian healthcare settings.
The study reviewed records of 174 adults with T2DM and APD who received omeprazole. Clinical outcomes at 120 days (visit 5) were compared with baseline (index visit), while safety was assessed through reported adverse events during the study period. Treatment with omeprazole was associated with substantial improvement in APD symptoms, including complete resolution of specific gastrointestinal manifestations (Table 1).
Cureus
An Evidence-Based Retrospective Study for the Management of Acid Peptic Disease With Omeprazole, a Proton Pump Inhibitor, in Indian Patients With Type 2 Diabetes Mellitus (PRIDE-1)
Bharat Saboo et al.
Comments (0)